Crohn's Zone (@CrohnsZoneBlog) profile picture

Crohn's suffer since 12/2011, Fecal transplant recipient (Thanks Mayo Clinic!), providing the latest news and research in Crohn's (Remission since June 2012)

Joined October 2012
Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)Photo by Crohn's Zone (@CrohnsZoneBlog)
Crohn's Zone retweeted
Stuck on tarmac at PHX. “Update in 7 hours” 🤡💩🤡💩
4
1
8
2,440
Crohn's Zone retweeted
No email for 11 hours and it has been glorious
5
1
2
85
3,135
Crohn's Zone retweeted
A new chapter begins for "Gut Check"! 🎙️ In this episode, we're saying farewell to longtime hosts Drs. Sam Eisenstein and Biddy Das and welcoming Drs. Irlna Tantchou and Pavel Mazirka as they take the mic. Join us as we reflect on memorable moments, share a few laughs, and look ahead to what's next for "Gut Check." 🔗 bit.ly/3YzjpvG @PubMEG
3
3
531
Crohn's Zone retweeted
Great couple of slides lining up the IL23 agents in UC. @ucsfibd @bruce_sands1
The 21st annual @ucsfibd conference kicks off with @bruce_sands1 and a state of the art lecture on UC. So how can appendectomy be both a risk factor for extension of proctitis AND a possible treatment? Interesting.
21
54
5,392
Crohn's Zone retweeted
Amazing experience for our IBD team @MayoClinicGIHep AZ with world renowned IUS guru Dr Christian Maaser as our visiting professor. Thanks @silverman_anna @MKaur_MD for setting up the workshop for the fellows! @BowelUltrasound
3
19
704
What a moment for the IBD community! 💜 Auburn University kicker Alex McPherson hit a 34-yard game-winning field goal as time expired to beat Georgia, the top-ranked team in the country, 27-24 last Saturday. Two years ago, ulcerative colitis kept him off the field for nearly the entire season. Alex has shared his journey living with IBD and an ostomy, and now he’s showing everyone what’s possible. Congratulations, Alex! You’re an inspiration to everyone living with Crohn’s disease and ulcerative colitis. 🏈 bit.ly/4ibPYJc
14
30
1,185
Got my hands on the SP robot! Love it
2
2
17
2,403
Crohn's Zone retweeted
The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR. The approval is based on results from the ATOMIC clinical trial led by Mayo Clinic. Learn more: mayocl.in/4yfvUM2
4
18
58
7,569
Crohn's Zone retweeted
Prof Florian Rieder: (OP-003) PALI-2108 (PDE4 inhibitor) for fibrostenosing Crohn’s was safe and possibly effective (n=5) with favorable PK and target engagement #uegweek2026
9
2
31
2,282
Crohn's Zone retweeted
Earlier this week I said the most important development in IBD of the last decade was... biosimilars. Here's the other half of the story. 20 new molecules in Phase 2 or later. Eight targets, plus dual-target combinations. If their trials succeed, up to six could be approved in Europe by 2031. TL1A is entering phase 3 readout time. Oral IL-23R blockade is in Phase 3. Co-formulated combination therapy is in Phase 3. Look at phase 2 and the pipeline is stacked. There’s even an anti-fibrotic for stricturing Crohn's. Biosimilars bought the headroom. This is what fills it. And it is very exciting. The limiting step now isn't the science. It's trial delivery: opening sites, finding eligible patients, research teams fitting studies around full clinical jobs. The good news? That's the part we can fix. Faster set-up, and every eligible patient offered a trial. That's how 2033 becomes 2031. Honestly, this is extraordinary.
8
25
4
77
9,316
A potential new option for one of Crohn’s disease’s toughest complications. New phase 3 FUZION data explored guselkumab for perianal fistulizing Crohn’s disease—with results that GEN Expert Pick Uma Mahadevan, MD, called notable: gastroendonews.com/a/iz0BAA/… #IBD
2
6
748
Very timely discussion on @mondaynightibd. Exciting new monoclonal antibodies are getting closer to entering the IBD treatment armamentarium: anti TL1A therapies. Several molecules are now competing in this race, with subtle but potentially important molecular differences in how they interact with TL1A and the TL1A DR3 pathway. So far, I would not call the efficacy results earthshattering. The bigger questions may be what makes this pathway truly different: 🔬 Can TL1A inhibition make a clinically meaningful dent in intestinal fibrosis, rather than simply control inflammation? 🧬 Could its future lie in combination therapy, as Spyre is exploring by combining TL1A blockade with other pathways? And one question I find particularly intriguing: 💭 Could TL1A inhibition eventually have a role in collagenous colitis, given the biology of mucosal inflammation and collagen deposition? The TL1A story may ultimately be less about another effective biologic and more about whether it can do something our current therapies cannot. Check out my LinkedIn post linkedin.com/posts/ibd-libra… #IBD #CrohnsDisease #UlcerativeColitis #TL1A @MondayNightIBD @DCharabaty @Bealoquebea @IBDimmunology @ShomronH @RPanaccione
1
7
13
1,629
Crohn's Zone retweeted
This thread is a great summary of what we know so far for the anti-TL1A antibodies for the treatment of #IBD Once we see the phase 3 data on these molecules we’ll have a better sense of how they fit in the algorithm
1
6
2
22
3,520
Important messages by @berinsj during @AmCollegeGastro Midwest PG Course. 6 Principles of acute severe ulcerative colitis management. 🕯️Colectomy rate is still bothersome in ASUC 🕯️JAKi may help produce a meaningful dent in colectomy rate 🕯️Never forget to address mental health early Patient education is critical
9
15
2,421
In February 2024, Propel a Cure awarded a 2-year, $100,000 Trailblazer Grant to Promakhos Therapeutics to advance an innovative approach to treating #Crohns disease. Promakhos is developing an oral, non-immunosuppressive precision therapy designed to restore a natural biological signal that appears to be missing in Crohn’s. With support from Propel a Cure and other funding sources, the team has made significant progress. In preclinical studies, the therapy has shown promising results by promoting intestinal healing, reducing bowel inflammation, improving the gut microbiome, and helping clear invasive microbes. The candidate drug also has a distinct mechanism of action that works upstream of current therapies and is paired with a biomarker strategy to help identify patients most likely to benefit. In Spring 2026, Promakhos co-founder and CEO @Katerina_Hatzi received the prestigious Harvard President’s Innovation Challenge Award, recognizing groundbreaking solutions to global challenges. The next milestone is advancing this promising therapy into human safety studies, bringing it one step closer to patients living with Crohn’s disease and others affected by inflammatory diseases.
6
8
369
Crohn's Zone retweeted
Fecal microbiota transplantation showed promise in slowing or reducing cognitive impairment in aging dogs and may be worth considering as an adjunct therapy in these cases. 🐕 Open access article: jav.ma/fmt1
2
1
7
785